{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:27:24Z","timestamp":1786973244907,"version":"build-2736575974"},"reference-count":242,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0038","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:55:45Z","timestamp":1786971345000},"source":"Crossref","is-referenced-by-count":0,"title":["Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"James","family":"Stevenson","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Wood","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara L.","family":"Aisner","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Axtell","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Bauman","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Bharat","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Dilling","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dowell","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Durm","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gettinger","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis E.","family":"Grotz","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Gubens","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy P.","family":"Lackner","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Levy","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy W.","family":"Loo","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lovly","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trey C.","family":"Mullikin","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ng","sequence":"additional","affiliation":[{"name":"The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio M.","family":"Polanco","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Riess","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lucia","family":"Ruano Mendez","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Tam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawee","family":"Tanvetyanon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yanagawa","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Yau","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yun","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gregory","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hang","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Key statistics about mesothelioma","unstructured":"American Cancer Society. Key statistics about mesothelioma. Accessed April 16, 2026. Available at https:\/\/www.cancer.org\/cancer\/types\/malignant-mesothelioma\/key-statistics.html"},{"key":"B2","series-title":"Int J Occup Environ Health","first-page":"1","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003\u20132008","volume":"19","author":"Henley SJ","year":"2013","unstructured":"Henley SJ, Larson TC, Wu M, Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003\u20132008. Int J Occup Environ Health 2013;19:1\u201310."},{"key":"B3","series-title":"JAMA Netw Open","first-page":"e2120360","article-title":"Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017","volume":"4","author":"Zhai Z","year":"2021","unstructured":"Zhai Z, Ruan J, Zheng Y, Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open 2021;4:e2120360."},{"key":"B4","series-title":"Arch Pathol Lab Med","first-page":"1251","article-title":"Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group","volume":"148","author":"Husain AN","year":"2024","unstructured":"Husain AN, Chapel DB, Attanoos R, Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2024;148:1251\u20131271."},{"key":"B5","series-title":"Nat Rev Dis Primers","first-page":"56","article-title":"Pleural mesothelioma","volume":"11","author":"Fennell DA","year":"2025","unstructured":"Fennell DA, Sekido Y, Baas P, Pleural mesothelioma. Nat Rev Dis Primers 2025;11:56."},{"key":"B6","series-title":"PLoS One","first-page":"e0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients","volume":"10","author":"Taioli E","year":"2015","unstructured":"Taioli E, Wolf AS, Camacho-Rivera M, Determinants of survival in malignant pleural mesothelioma: a Surveillance, Epidemiology, and End Results (SEER) study of 14,228 patients. PLoS One 2015;10:e0145039."},{"key":"B7","article-title":"Special section: rare cancers in adults","unstructured":"American Cancer Society. Special section: rare cancers in adults. Accessed June 22, 2026. Available at: https:\/\/tinyurl.com\/yb4joe3c"},{"key":"B8","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"214","article-title":"Malignant mesothelioma mortality - United States, 1999\u20132015","volume":"66","author":"Mazurek JM","year":"2017","unstructured":"Mazurek JM, Syamlal G, Wood JM, Malignant mesothelioma mortality - United States, 1999\u20132015. MMWR Morb Mortal Wkly Rep 2017;66:214\u2013218."},{"key":"B9","series-title":"J Surg Res","first-page":"23","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff RR","year":"2015","unstructured":"Meyerhoff RR, Yang CF, Speicher PJ, Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:23\u201332."},{"key":"B10","series-title":"Eur Respir J","first-page":"1420","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk AW","year":"2011","unstructured":"Musk AW, Olsen N, Alfonso H, Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:1420\u20131424."},{"key":"B11","series-title":"Br J Cancer","first-page":"1860","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton A","year":"2014","unstructured":"Linton A, Pavlakis N, O\u2019Connell R, Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111:1860\u20131869."},{"key":"B12","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"645","article-title":"Malignant mesothelioma mortality in women - United States, 1999\u20132020","volume":"71","author":"Mazurek JM","year":"2022","unstructured":"Mazurek JM, Blackley DJ, Weissman DN. Malignant mesothelioma mortality in women - United States, 1999\u20132020. MMWR Morb Mortal Wkly Rep 2022;71:645\u2013649."},{"key":"B13","series-title":"Lancet Oncol","first-page":"1022","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta G","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 2017;18:1022\u20131039."},{"key":"B14","series-title":"CA Cancer J Clin","first-page":"261","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis CE","year":"2017","unstructured":"DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States. CA Cancer J Clin 2017;67:261\u2013272."},{"key":"B15","series-title":"J Occup Med","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear BP","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34:718\u2013721."},{"key":"B16","series-title":"Cancer","first-page":"2736","article-title":"Latency of asbestos disease among insulation workers in the United States and Canada","volume":"46","author":"Selikoff IJ","year":"1980","unstructured":"Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980;46:2736\u20132740."},{"key":"B17","series-title":"Thorax","first-page":"6","article-title":"Diffuse malignant pleural mesothelioma and asbestos exposure","volume":"26","author":"Whitwell F","year":"1971","unstructured":"Whitwell F, Rawcliffe RM. Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax 1971;26:6\u201322."},{"key":"B18","series-title":"J Thorac Oncol","first-page":"792","article-title":"Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study","volume":"18","author":"Huang J","year":"2023","unstructured":"Huang J, Chan SC, Pang WS, Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol 2023;18:792\u2013802."},{"key":"B19","series-title":"Environ Health","first-page":"90","article-title":"Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis","volume":"17","author":"Xu R","year":"2018","unstructured":"Xu R, Barg FK, Emmett EA, Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis. Environ Health 2018;17:90."},{"key":"B20","series-title":"Occup Environ Med","first-page":"838","article-title":"Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis","volume":"74","author":"Marsh GM","year":"2017","unstructured":"Marsh GM, Riordan AS, Keeton KA, Benson SM. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med 2017;74:838\u2013846."},{"key":"B21","series-title":"Toxics","first-page":"20","article-title":"Occupational and environmental asbestos exposure and survival of patients with asbestos-related cancer: a follow-up study on patients with malignant mesothelioma and asbestos-related lung cancer in Korea","volume":"12","author":"Kang MS","year":"2023","unstructured":"Kang MS, Chae WR, Lee YJ, Moon KW. Occupational and environmental asbestos exposure and survival of patients with asbestos-related cancer: a follow-up study on patients with malignant mesothelioma and asbestos-related lung cancer in Korea. Toxics 2023;12:20."},{"key":"B22","series-title":"Pain Med","first-page":"1303","article-title":"A retrospective study of chest pain in benign asbestos pleural disease","volume":"12","author":"Allen RK","year":"2011","unstructured":"Allen RK, Cramond T, Lennon D, Waterhouse M. A retrospective study of chest pain in benign asbestos pleural disease. Pain Med 2011;12:1303\u20131308."},{"key":"B23","series-title":"Rev Mal Respir","first-page":"e11","article-title":"Asbestos-related cancer risk in patients with asbestosis or pleural plaques","volume":"28","author":"Ameille J","year":"2011","unstructured":"Ameille J, Brochard P, Letourneux M, Asbestos-related cancer risk in patients with asbestosis or pleural plaques. Rev Mal Respir 2011;28:e11\u201317."},{"key":"B24","series-title":"Cancer Causes Control","first-page":"971","article-title":"Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma","volume":"28","author":"Chang ET","year":"2017","unstructured":"Chang ET, Lau EC, Mowat FS, Teta MJ. Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma. Cancer Causes Control 2017;28:971\u2013979."},{"key":"B25","series-title":"Arch Pathol Lab Med","first-page":"1129","article-title":"Malignant (diffuse) mesothelioma in patients with hematologic malignancies: a clinicopathologic study of 45 cases","volume":"139","author":"Li X","year":"2015","unstructured":"Li X, Brownlee NA, Sporn TA, Malignant (diffuse) mesothelioma in patients with hematologic malignancies: a clinicopathologic study of 45 cases. Arch Pathol Lab Med 2015;139:1129\u20131136."},{"key":"B26","series-title":"Cancer Causes Control","first-page":"1237","article-title":"Ionizing radiation: a risk factor for mesothelioma","volume":"20","author":"Goodman JE","year":"2009","unstructured":"Goodman JE, Nascarella MA, Valberg PA. Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 2009;20:1237\u20131254."},{"key":"B27","series-title":"J Clin Oncol","first-page":"4544","article-title":"Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma","volume":"31","author":"Chirieac LR","year":"2013","unstructured":"Chirieac LR, Barletta JA, Yeap BY, Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol 2013;31:4544\u20134549."},{"key":"B28","series-title":"J Clin Oncol","first-page":"1489","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson DC","year":"2007","unstructured":"Hodgson DC, Gilbert ES, Dores GM, Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma. J Clin Oncol 2007;25:1489\u20131497."},{"key":"B29","series-title":"Am J Clin Oncol","first-page":"294","article-title":"An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma","volume":"30","author":"Deutsch M","year":"2007","unstructured":"Deutsch M, Land SR, Begovic M, An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol 2007;30:294\u2013296."},{"key":"B30","series-title":"J Natl Cancer Inst","first-page":"1354","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors","volume":"97","author":"Travis LB","year":"2005","unstructured":"Travis LB, Fossa SD, Schonfeld SJ, Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354\u20131365."},{"key":"B31","series-title":"Cancer","first-page":"1432","article-title":"Therapeutic radiation for lymphoma: risk of malignant mesothelioma","volume":"109","author":"Teta MJ","year":"2007","unstructured":"Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007;109:1432\u20131438."},{"key":"B32","series-title":"Blood","first-page":"3679","article-title":"Malignant mesothelioma after radiation treatment for Hodgkin lymphoma","volume":"113","author":"De Bruin ML","year":"2009","unstructured":"De Bruin ML, Burgers JA, Baas P, Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009;113:3679\u20133681."},{"key":"B33","series-title":"Cancer","first-page":"1379","article-title":"Post-irradiation malignant mesothelioma","volume":"77","author":"Cavazza A","year":"1996","unstructured":"Cavazza A, Travis LB, Travis WD, Post-irradiation malignant mesothelioma. Cancer 1996;77:1379\u20131385."},{"key":"B34","series-title":"Lung Cancer","first-page":"410","article-title":"Malignant mesothelioma following thoracic radiotherapy for lung cancer","volume":"57","author":"Witherby SM","year":"2007","unstructured":"Witherby SM, Butnor KJ, Grunberg SM. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer 2007;57:410\u2013413."},{"key":"B35","series-title":"Cancer Med","first-page":"778","article-title":"Relationship between exposure to ionizing radiation and mesothelioma risk: a systematic review of the scientific literature and meta-analysis","volume":"11","author":"Visci G","year":"2022","unstructured":"Visci G, Rizzello E, Zunarelli C, Relationship between exposure to ionizing radiation and mesothelioma risk: a systematic review of the scientific literature and meta-analysis. Cancer Med 2022;11:778\u2013789."},{"key":"B36","series-title":"J Thorac Oncol","first-page":"1246","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone M","year":"2016","unstructured":"Carbone M, Kanodia S, Chao A, Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 2016;11:1246\u20131262."},{"key":"B37","series-title":"J Thorac Oncol","first-page":"731","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada","volume":"10","author":"Baumann F","year":"2015","unstructured":"Baumann F, Buck BJ, Metcalf RV, The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada. J Thorac Oncol 2015;10:731\u2013737."},{"key":"B38","series-title":"Environ Geochem Health","first-page":"419","article-title":"Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease","volume":"35","author":"Van Gosen BS","year":"2013","unstructured":"Van Gosen BS, Blitz TA, Plumlee GS, Geologic occurrences of erionite in the United States: an emerging national public health concern for respiratory disease. Environ Geochem Health 2013;35:419\u2013430."},{"key":"B39","series-title":"Proc Natl Acad Sci U S A","first-page":"13618","article-title":"Erionite exposure in North Dakota and Turkish villages with mesothelioma","volume":"108","author":"Carbone M","year":"2011","unstructured":"Carbone M, Baris YI, Bertino P, Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 2011;108:13618\u201313623."},{"key":"B40","series-title":"Ann Work Expo Health","first-page":"677","article-title":"Environmental and occupational exposure to erionite and related health risks: progress and prospects","volume":"69","author":"Chen G","year":"2025","unstructured":"Chen G, Mannetje A, Salmond JA, Douwes J. Environmental and occupational exposure to erionite and related health risks: progress and prospects. Ann Work Expo Health 2025;69:677\u2013692."},{"key":"B41","series-title":"J Thorac Oncol","first-page":"873","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone M","year":"2022","unstructured":"Carbone M, Pass HI, Ak G, Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations. J Thorac Oncol 2022;17:873\u2013889."},{"key":"B42","series-title":"Diagnostics (Basel)","first-page":"1710","article-title":"Diagnostics of BAP1-tumor predisposition syndrome by a multitesting approach: a ten-year-long experience","volume":"12","author":"Sculco M","year":"2022","unstructured":"Sculco M, La Vecchia M, Aspesi A, Diagnostics of BAP1-tumor predisposition syndrome by a multitesting approach: a ten-year-long experience. Diagnostics (Basel) 2022;12:1710."},{"key":"B43","series-title":"GeneReviews\u00ae.","article-title":"BAP1 Tumor Predisposition Syndrome","author":"Pilarski R","year":"1993","unstructured":"Pilarski R, Carlo MI, Cebulla C, BAP1 Tumor Predisposition Syndrome. In: Adam MP, Mirzaa GM, Pagon RA, eds. GeneReviews\u00ae. Seattle, WA: University of Washington, Seattle; 1993."},{"key":"B44","series-title":"J Natl Cancer Inst","first-page":"1328","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole S","year":"2018","unstructured":"Walpole S, Pritchard AL, Cebulla CM, Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst 2018;110:1328\u20131341."},{"key":"B45","series-title":"J Clin Oncol","first-page":"JCO2018790352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino S","year":"2018","unstructured":"Pastorino S, Yoshikawa Y, Pass HI, A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol 2018;36:JCO2018790352."},{"key":"B46","series-title":"Cancer Lett","first-page":"38","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti M","year":"2017","unstructured":"Betti M, Casalone E, Ferrante D, Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett 2017;405:38\u201345."},{"key":"B47","series-title":"Cancer Res","first-page":"206","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar JA","year":"2016","unstructured":"Ohar JA, Cheung M, Talarchek J, Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 2016;76:206\u2013215."},{"key":"B48","series-title":"Carcinogenesis","first-page":"76","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann F","year":"2015","unstructured":"Baumann F, Flores E, Napolitano A, Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015;36:76\u201381."},{"key":"B49","series-title":"J Transl Med","first-page":"179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone M","year":"2012","unstructured":"Carbone M, Ferris LK, Baumann F, BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179."},{"key":"B50","series-title":"Nat Genet","first-page":"1022","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa JR","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022\u20131025."},{"key":"B51","series-title":"J Toxicol Environ Health B Crit Rev","first-page":"76","article-title":"Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos","volume":"14","author":"Mossman BT","year":"2011","unstructured":"Mossman BT, Lippmann M, Hesterberg TW, Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev 2011;14:76\u2013121."},{"key":"B52","series-title":"StatPearls [Internet]","article-title":"Malignant Mesothelioma","author":"Syed HA","year":"2026","unstructured":"Syed HA, Wallen JM. Malignant Mesothelioma. In StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2026."},{"key":"B53","series-title":"Eur J Radiol","first-page":"124","article-title":"Low-dose chest computed tomography screening of subjects exposed to asbestos","volume":"101","author":"Kato K","year":"2018","unstructured":"Kato K, Gemba K, Ashizawa K, Low-dose chest computed tomography screening of subjects exposed to asbestos. Eur J Radiol 2018;101:124\u2013128."},{"key":"B54","series-title":"Am J Respir Crit Care Med","first-page":"90","article-title":"Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort","volume":"188","author":"Markowitz SB","year":"2013","unstructured":"Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. Am J Respir Crit Care Med 2013;188:90\u201396."},{"key":"B55","series-title":"Ann Surg","first-page":"1069","article-title":"Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review","volume":"255","author":"Sorensen LT.","year":"2012","unstructured":"Sorensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012;255:1069\u20131079."},{"key":"B56","series-title":"Int Arch Occup Environ Health","first-page":"195","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten MK","year":"2014","unstructured":"Felten MK, Khatab K, Knoll L, Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health 2014;87:195\u2013204."},{"key":"B57","series-title":"BMJ Open","first-page":"e017104","article-title":"Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study","volume":"7","author":"Casjens S","year":"2017","unstructured":"Casjens S, Weber DG, Johnen G, Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open 2017;7:e017104."},{"key":"B58","series-title":"BMC Cancer","first-page":"386","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen G","year":"2017","unstructured":"Johnen G, Gawrych K, Raiko I, Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer 2017;17:386."},{"key":"B59","series-title":"Eur Respir J","first-page":"479","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel A","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479\u2013495."},{"key":"B60","series-title":"Am J Respir Crit Care Med","first-page":"781","article-title":"Screening for mesothelioma: more harm than good?","volume":"178","author":"van Meerbeeck JP","year":"2008","unstructured":"van Meerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med 2008;178:781\u2013782."},{"key":"B61","series-title":"J Thorac Oncol","first-page":"620","article-title":"Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure","volume":"4","author":"Roberts HC","year":"2009","unstructured":"Roberts HC, Patsios DA, Paul NS, Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 2009;4:620\u2013628."},{"key":"B62","series-title":"Semin Thorac Cardiovasc Surg","first-page":"97","article-title":"Current status of screening for malignant pleural mesothelioma","volume":"21","author":"Pass HI","year":"2009","unstructured":"Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97\u2013104."},{"key":"B63","series-title":"N Engl J Med","first-page":"503","article-title":"Reduced lung- cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning HJ","year":"2020","unstructured":"de Koning HJ, van der Aalst CM, de Jong PA, Reduced lung- cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503\u2013513."},{"key":"B64","series-title":"J Thorac Oncol","first-page":"1732","article-title":"Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial","volume":"14","year":"2019","unstructured":"National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the National Lung Screening Trial. J Thorac Oncol 2019;14:1732\u20131742."},{"key":"B65","series-title":"Ann Oncol","first-page":"v31","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas P","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015.;26(Suppl 5):v31\u201339."},{"key":"B66","series-title":"N Engl J Med","first-page":"395","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle DR","year":"2011","unstructured":"Aberle DR, Adams AM, Berg CD, Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395\u2013409."},{"key":"B67","series-title":"J Thorac Dis","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk N","year":"2013","unstructured":"van Zandwijk N, Clarke C, Henderson D, Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis 2013;5:E254\u2013307."},{"key":"B68","series-title":"J Thorac Imaging","first-page":"W64","article-title":"ACR Appropriateness Criteria\u00ae chronic dyspnea: suspected pulmonary origin","volume":"28","author":"Dyer DS","year":"2013","unstructured":"Dyer DS, Mohammed TL, Kirsch J, ACR Appropriateness Criteria\u00ae chronic dyspnea: suspected pulmonary origin. J Thorac Imaging 2013;28:W64\u201366."},{"key":"B69","series-title":"Ann Am Thorac Soc","first-page":"1075","article-title":"Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review","volume":"11","author":"Miller AC","year":"2014","unstructured":"Miller AC, Miettinen M, Schrump DS, Hassan R. Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc 2014;11:1075\u20131081."},{"key":"B70","series-title":"J Clin Med","first-page":"2434","article-title":"When the diagnosis of mesothelioma challenges textbooks and guidelines","volume":"10","author":"Rossi G","year":"2021","unstructured":"Rossi G, Davoli F, Poletti V, When the diagnosis of mesothelioma challenges textbooks and guidelines. J Clin Med 2021;10:2434."},{"key":"B71","series-title":"J Am Coll Radiol","first-page":"S188","article-title":"ACR Appropriateness Criteria occupational lung diseases","volume":"17","author":"Cox CW","year":"2020","unstructured":"Cox CW, Chung JH, Ackman JB, ACR Appropriateness Criteria occupational lung diseases. J Am Coll Radiol 2020;17:S188\u2013197."},{"key":"B72","series-title":"Lung Cancer","first-page":"148","article-title":"Imaging in pleural mesothelioma: a review of the 12th International Conference of the International Mesothelioma Interest Group","volume":"90","author":"Armato SG","year":"2015","unstructured":"Armato SG, Coolen J, Nowak AK, Imaging in pleural mesothelioma: a review of the 12th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2015;90:148\u2013154."},{"key":"B73","series-title":"Lung Cancer","first-page":"190","article-title":"Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group","volume":"82","author":"Armato SG","year":"2013","unstructured":"Armato SG, Labby ZE, Coolen J, Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2013;82:190\u2013196."},{"key":"B74","series-title":"J Thorac Oncol","first-page":"602","article-title":"Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma","volume":"6","author":"Kao SC","year":"2011","unstructured":"Kao SC, Yan TD, Lee K, Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol 2011;6:602\u2013605."},{"key":"B75","series-title":"Eur Respir J","first-page":"1900953","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel A","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020;55:1900953."},{"key":"B76","series-title":"Cancer","first-page":"2248","article-title":"Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma","volume":"110","author":"Greillier L","year":"2007","unstructured":"Greillier L, Cavailles A, Fraticelli A, Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110:2248\u20132252."},{"key":"B77","series-title":"J Clin Oncol","first-page":"1006","article-title":"Treatment of pleural mesothelioma: ASCO guideline update","volume":"43","author":"Kindler HL","year":"2025","unstructured":"Kindler HL, Ismaila N, Bazhenova L, Treatment of pleural mesothelioma: ASCO guideline update. J Clin Oncol 2025;43:1006\u20131038."},{"key":"B78","series-title":"J Clin Pathol","first-page":"847","article-title":"Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson DW","year":"2013","unstructured":"Henderson DW, Reid G, Kao SC, Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 2013;66:847\u2013853."},{"key":"B79","series-title":"Cancer Cytopathol","first-page":"703","article-title":"The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey","volume":"121","author":"Paintal A","year":"2013","unstructured":"Paintal A, Raparia K, Zakowski MF, Nayar R. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol 2013;121:703\u2013707."},{"key":"B80","series-title":"J Clin Oncol","first-page":"1541","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet K","year":"2012","unstructured":"Hollevoet K, Reitsma JB, Creaney J, Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541\u20131549."},{"key":"B81","series-title":"J Thorac Oncol","first-page":"1317","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider J","year":"2008","unstructured":"Schneider J, Hoffmann H, Dienemann H, Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317\u20131324."},{"key":"B82","series-title":"Respir Med","first-page":"149","article-title":"Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis","volume":"104","author":"Luo L","year":"2010","unstructured":"Luo L, Shi HZ, Liang QL, Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010;104:149\u2013156."},{"key":"B83","series-title":"Am J Respir Crit Care Med","first-page":"620","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet K","year":"2010","unstructured":"Hollevoet K, Nackaerts K, Thimpont J, Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620\u2013625."},{"key":"B84","series-title":"Am J Respir Crit Care Med","first-page":"839","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman DJ","year":"2018","unstructured":"Feller-Kopman DJ, Reddy CB, DeCamp MM, Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline. Am J Respir Crit Care Med 2018;198:839\u2013849."},{"key":"B85","series-title":"JAMA","first-page":"1903","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas R","year":"2017","unstructured":"Thomas R, Fysh ETH, Smith NA, Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017;318:1903\u20131912."},{"key":"B86","series-title":"N Engl J Med","first-page":"1313","article-title":"Outpatient talc administration by indwelling pleural catheter for malignant effusion","volume":"378","author":"Bhatnagar R","year":"2018","unstructured":"Bhatnagar R, Keenan EK, Morley AJ, Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med 2018;378:1313\u20131322."},{"key":"B87","series-title":"Lung Cancer","first-page":"9","article-title":"A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14)","volume":"108","author":"Boshuizen RC","year":"2017","unstructured":"Boshuizen RC, Vd Noort V, Burgers JA, A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer 2017;108:9\u201314."},{"key":"B88","series-title":"Ann Thorac Surg","first-page":"1053","article-title":"Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions","volume":"94","author":"Hunt BM","year":"2012","unstructured":"Hunt BM, Farivar AS, Vallieres E, Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg 2012;94:1053\u20131057; discussion 1057\u20131059."},{"key":"B89","series-title":"Chest","first-page":"362","article-title":"Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion","volume":"129","author":"Tremblay A","year":"2006","unstructured":"Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006;129:362\u2013368."},{"key":"B90","series-title":"Thorac Cardiovasc Surg","first-page":"42","article-title":"Recurrent pleural effusion: who benefits from a tunneled pleural catheter?","volume":"57","author":"Schneider T","year":"2009","unstructured":"Schneider T, Reimer P, Storz K, Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg 2009;57:42\u201346."},{"key":"B91","series-title":"Interact Cardiovasc Thorac Surg","first-page":"818","article-title":"What is the best treatment for malignant pleural effusions?","volume":"12","author":"Zahid I","year":"2011","unstructured":"Zahid I, Routledge T, Bille A, Scarci M. What is the best treatment for malignant pleural effusions? Interact Cardiovasc Thorac Surg 2011;12:818\u2013823."},{"key":"B92","series-title":"Surg Endosc","first-page":"919","article-title":"Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients","volume":"20","author":"Arapis K","year":"2006","unstructured":"Arapis K, Caliandro R, Stern JB, Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc 2006;20:919\u2013923."},{"key":"B93","article-title":"WHO Classification of Tumours: Thoracic Tumours","year":"2021","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Thoracic Tumours, 5th edition. Lyon, France: International Agency for Research on Cancer; 2021."},{"key":"B94","series-title":"J Thorac Oncol","first-page":"608","article-title":"The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 Classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 Classification. J Thorac Oncol 2022;17:608\u2013622."},{"key":"B95","series-title":"Mod Pathol","first-page":"281","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel","volume":"33","author":"Marchevsky AM","year":"2020","unstructured":"Marchevsky AM, Khoor A, Walts AE, Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol 2020;33:281\u2013296."},{"key":"B96","series-title":"Mod Pathol","first-page":"2269","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung YP","year":"2020","unstructured":"Hung YP, Dong F, Torre M, Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269\u20132279."},{"key":"B97","series-title":"Mod Pathol","first-page":"271","article-title":"Molecular characterization of localized pleural mesothelioma","volume":"33","author":"Hung YP","year":"2020","unstructured":"Hung YP, Dong F, Dubuc AM, Molecular characterization of localized pleural mesothelioma. Mod Pathol 2020;33:271\u2013280."},{"key":"B98","series-title":"Am J Surg Pathol","first-page":"866","article-title":"Localized malignant mesothelioma","volume":"29","author":"Allen TC","year":"2005","unstructured":"Allen TC, Cagle PT, Churg AM, Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866\u2013873."},{"key":"B99","series-title":"J Thorac Cardiovasc Surg","first-page":"363","article-title":"Localized mesothelioma of the pleura: benign and malignant variants","volume":"75","author":"Okike N","year":"1978","unstructured":"Okike N, Bernatz PE, Woolner LB. Localized mesothelioma of the pleura: benign and malignant variants. J Thorac Cardiovasc Surg 1978;75:363\u2013372."},{"key":"B100","series-title":"Arch Pathol Lab Med","first-page":"89","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain AN","year":"2018","unstructured":"Husain AN, Colby TV, Ordonez NG, Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018;142:89\u2013108."},{"key":"B101","series-title":"Histopathology","first-page":"633","article-title":"Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"84","author":"Klebe S","year":"2024","unstructured":"Klebe S, Judge M, Brcic L, Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 2024;84:633\u2013645."},{"key":"B102","series-title":"Hum Pathol","first-page":"160","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky AM","year":"2017","unstructured":"Marchevsky AM, LeStang N, Hiroshima K, The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol 2017;67:160\u2013168."},{"key":"B103","series-title":"Hum Pathol","first-page":"1","article-title":"What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update","volume":"38","author":"Ordonez NG.","year":"2007","unstructured":"Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol 2007;38:1\u201316."},{"key":"B104","series-title":"J Clin Oncol","first-page":"1343","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler HL","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG, Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1343\u20131373."},{"key":"B105","series-title":"Chest","first-page":"888","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment","volume":"136","author":"Ray M","year":"2009","unstructured":"Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009;136:888\u2013896."},{"key":"B106","series-title":"Histopathology","first-page":"261","article-title":"Claudin-4 in mesothelioma diagnosis","volume":"51","author":"Facchetti F","year":"2007","unstructured":"Facchetti F, Gentili F, Lonardi S, Claudin-4 in mesothelioma diagnosis. Histopathology 2007;51:261\u2013263."},{"key":"B107","series-title":"Arch Pathol Lab Med","first-page":"1407","article-title":"Immunohistochemical diagnosis of epithelioid mesothelioma: an update","volume":"129","author":"Ordonez NG.","year":"2005","unstructured":"Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407\u20131414."},{"key":"B108","series-title":"Arch Pathol Lab Med","first-page":"241","article-title":"Epithelioid lesions of the serosa","volume":"136","author":"Anttila S.","year":"2012","unstructured":"Anttila S. Epithelioid lesions of the serosa. Arch Pathol Lab Med 2012;136:241\u2013252."},{"key":"B109","article-title":"Protocol for the Examination of Specimens from Patients with Diffuse Pleural Mesothelioma","author":"Raparia K","unstructured":"Raparia K, Schneider F, Roden A, Protocol for the Examination of Specimens from Patients with Diffuse Pleural Mesothelioma. Accessed June 22, 2026. Available at: https:\/\/documents.cap.org\/protocols\/PleuraPericard_5.0.0.0.REL.CAPCP.pdf"},{"key":"B110","series-title":"Hum Pathol","first-page":"9","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici J","year":"2016","unstructured":"Andrici J, Jung J, Sheen A, Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 2016;51:9\u201315."},{"key":"B111","series-title":"Pathology","first-page":"336","article-title":"Loss of expression of BAP1 is very rare in non-small cell lung carcinoma","volume":"48","author":"Andrici J","year":"2016","unstructured":"Andrici J, Parkhill TR, Jung J, Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology 2016;48:336\u2013340."},{"key":"B112","series-title":"Am J Surg Pathol","first-page":"e100","article-title":"The separation of benign and malignant mesothelial proliferations: new markers and how to use them","volume":"44","author":"Churg A","year":"2020","unstructured":"Churg A, Naso JR. The separation of benign and malignant mesothelial proliferations: new markers and how to use them. Am J Surg Pathol 2020;44:e100\u2013112."},{"key":"B113","series-title":"Genome Med","first-page":"58","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney J","year":"2022","unstructured":"Creaney J, Patch AM, Addala V, Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med 2022;14:58."},{"key":"B114","series-title":"Am J Surg Pathol","first-page":"980","article-title":"A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules P","year":"2017","unstructured":"Desmeules P, Joubert P, Zhang L, A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions. Am J Surg Pathol 2017;41:980\u2013988."},{"key":"B115","series-title":"Mol Oncol","first-page":"1207","article-title":"Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival","volume":"14","author":"Quetel L","year":"2020","unstructured":"Quetel L, Meiller C, Assie JB, Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol 2020;14:1207\u20131223."},{"key":"B116","series-title":"Cancer Discov","first-page":"1548","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak J","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 2018;8:1548\u20131565."},{"key":"B117","series-title":"Nat Genet","first-page":"407","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno R","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407\u2013416."},{"key":"B118","series-title":"Cancer Res","first-page":"264","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo G","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264\u2013269."},{"key":"B119","series-title":"Lung Cancer","first-page":"154","article-title":"NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer","volume":"146","author":"Leal JL","year":"2020","unstructured":"Leal JL, Peters G, Szaumkessel M, NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. Lung Cancer 2020;146:154\u2013159."},{"key":"B120","series-title":"Pathol Res Pract","first-page":"153772","article-title":"Malignant pleural mesothelioma with an EML4-ALK fusion: expect the unexpected!","volume":"231","author":"Cordier F","year":"2022","unstructured":"Cordier F, Van der Meulen J, van Roy N, Malignant pleural mesothelioma with an EML4-ALK fusion: expect the unexpected! Pathol Res Pract 2022;231:153772."},{"key":"B121","series-title":"Lung Cancer","first-page":"47","article-title":"Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement","volume":"142","author":"Bronte G","year":"2020","unstructured":"Bronte G, Delmonte A, Burgio MA, Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. Lung Cancer 2020;142:47\u201350."},{"key":"B122","series-title":"J Thorac Oncol","first-page":"455","article-title":"Molecular characterization of peritoneal mesotheliomas","volume":"17","author":"Offin M","year":"2022","unstructured":"Offin M, Yang SR, Egger J, Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol 2022;17:455\u2013460."},{"key":"B123","series-title":"Insights Imaging","first-page":"729","article-title":"Imaging characteristics of pleural tumours","volume":"6","author":"De Paoli L","year":"2015","unstructured":"De Paoli L, Quaia E, Poillucci G, Imaging characteristics of pleural tumours. Insights Imaging 2015;6:729\u2013740."},{"key":"B124","series-title":"Ann Thorac Surg","first-page":"862","article-title":"Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma","volume":"88","author":"Rice DC","year":"2009","unstructured":"Rice DC, Steliga MA, Stewart J, Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009;88:862\u2013868; discussion 868\u2013869."},{"key":"B125","series-title":"Eur J Cardiothorac Surg","first-page":"497","article-title":"The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma","volume":"25","author":"Pilling JE","year":"2004","unstructured":"Pilling JE, Stewart DJ, Martin-Ucar AE, The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004;25:497\u2013501."},{"key":"B126","series-title":"Eur J Cardiothorac Surg","first-page":"619","article-title":"Mesothelioma\u2013VATS biopsy and lung mobilization improves diagnosis and palliation","volume":"16","author":"Grossebner MW","year":"1999","unstructured":"Grossebner MW, Arifi AA, Goddard M, Ritchie AJ. Mesothelioma\u2013VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 1999;16:619\u2013623."},{"key":"B127","series-title":"Lung Cancer","first-page":"418","article-title":"False positive 18F-FDG-PET\/CT in a patient after talc pleurodesis","volume":"58","author":"Ahmadzadehfar H","year":"2007","unstructured":"Ahmadzadehfar H, Palmedo H, Strunk H, False positive 18F-FDG-PET\/CT in a patient after talc pleurodesis. Lung Cancer 2007;58:418\u2013421."},{"key":"B128","series-title":"Clin Nucl Med","first-page":"886","article-title":"F-18 FDG PET\/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study","volume":"34","author":"Nguyen NC","year":"2009","unstructured":"Nguyen NC, Tran I, Hueser CN, F-18 FDG PET\/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med 2009;34:886\u2013890."},{"key":"B129","series-title":"Thorac Cardiovasc Surg","first-page":"215","article-title":"Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma","volume":"58","author":"Pilling J","year":"2010","unstructured":"Pilling J, Dartnell JA, Lang-Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg 2010;58:215\u2013219."},{"key":"B130","article-title":"About FDA","unstructured":"U.S. Food & Drug Administration. About FDA. Accessed April 10, 2026. Available at: https:\/\/www.fda.gov\/"},{"key":"B131","series-title":"J Clin Oncol","first-page":"2636","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang NJ","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636\u20132644."},{"key":"B132","series-title":"Clin Lung Cancer","first-page":"30","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou N","year":"2010","unstructured":"Katirtzoglou N, Gkiozos I, Makrilia N, Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010;11:30\u201335."},{"key":"B133","series-title":"J Clin Oncol","first-page":"1443","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli GL","year":"2006","unstructured":"Ceresoli GL, Zucali PA, Favaretto AG, Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443\u20131448."},{"key":"B134","series-title":"Ann Oncol","first-page":"370","article-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","volume":"19","author":"Castagneto B","year":"2008","unstructured":"Castagneto B, Botta M, Aitini E, Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370\u2013373."},{"key":"B135","series-title":"J Thorac Oncol","first-page":"756","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro A","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008;3:756\u2013763."},{"key":"B136","series-title":"Lancet","first-page":"1405","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman G","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405\u20131414."},{"key":"B137","series-title":"Br J Cancer","first-page":"552","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli GL","year":"2013","unstructured":"Ceresoli GL, Zucali PA, Mencoboni M, Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013;109:552\u2013558."},{"key":"B138","series-title":"Cancer Chemother Pharmacol","first-page":"975","article-title":"A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma","volume":"73","author":"Arrieta O","year":"2014","unstructured":"Arrieta O, Lopez-Macias D, Mendoza-Garcia VO, A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol 2014;73:975\u2013982."},{"key":"B139","series-title":"Br J Cancer","first-page":"342","article-title":"Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma","volume":"86","author":"van Haarst JM","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold C, Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342\u2013345."},{"key":"B140","series-title":"Br J Cancer","first-page":"491","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak AK","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R, A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491\u2013496."},{"key":"B141","series-title":"Cancer","first-page":"2791","article-title":"Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study","volume":"97","author":"Favaretto AG","year":"2003","unstructured":"Favaretto AG, Aversa SM, Paccagnella A, Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003;97:2791\u20132797."},{"key":"B142","series-title":"J Clin Oncol","first-page":"1556","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti GV","year":"2003","unstructured":"Scagliotti GV, Shin D-M, Kindler HL, Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556\u20131561."},{"key":"B143","series-title":"J Thorac Oncol","first-page":"764","article-title":"Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"Taylor P","year":"2008","unstructured":"Taylor P, Castagneto B, Dark G, Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3:764\u2013771."},{"key":"B144","series-title":"Lancet","first-page":"1685","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers MF","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P, Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685\u20131694."},{"key":"B145","series-title":"Lancet","first-page":"375","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375\u2013386."},{"key":"B146","series-title":"Ann Oncol","first-page":"488","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters S","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022;33:488\u2013499."},{"key":"B147","series-title":"J Clin Oncol","first-page":"742","article-title":"Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743","volume":"44","author":"Scherpereel A","year":"2026","unstructured":"Scherpereel A, Baas P, Nowak AK, Five-year clinical outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma in CheckMate 743. J Clin Oncol 2026;44:742\u2013749."},{"key":"B148","series-title":"Lancet","first-page":"2295","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu Q","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 2023;402:2295\u20132306."},{"key":"B149","series-title":"Ann Oncol","first-page":"548","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip E","year":"2025","unstructured":"Felip E, Popat S, Dafni U, A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. Ann Oncol 2025;36:548\u2013560."},{"key":"B150","series-title":"JAMA Oncol","first-page":"1607","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino M","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:1607\u20131616."},{"key":"B151","series-title":"J Clin Oncol","first-page":"709","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo J","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709\u2013717."},{"key":"B152","series-title":"Curr Drug Saf","first-page":"62","article-title":"Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management","volume":"11","author":"Sgambato A","year":"2016","unstructured":"Sgambato A, Casaluce F, Sacco PC, Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non- small cell lung cancer (NSCLC): a review on toxicity profile and its management. Curr Drug Saf 2016;11:62\u201368."},{"key":"B153","series-title":"Urology","first-page":"166","article-title":"Malignant mesothelioma of the tunica vaginalis testis: outcomes following surgical management beyond radical orchiectomy","volume":"107","author":"Recabal P","year":"2017","unstructured":"Recabal P, Rosenzweig B, Bazzi WM, Malignant mesothelioma of the tunica vaginalis testis: outcomes following surgical management beyond radical orchiectomy. Urology 2017;107:166\u2013170."},{"key":"B154","series-title":"J Korean Med Sci","first-page":"1879","article-title":"A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin","volume":"32","author":"Kim JS","year":"2017","unstructured":"Kim JS, Lim SY, Hwang J, A case report of primary pericardial malignant mesothelioma treated with pemetrexed and cisplatin. J Korean Med Sci 2017;32:1879\u20131884."},{"key":"B155","series-title":"Lancet Oncol","first-page":"1530","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell DA","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530\u20131540."},{"key":"B156","series-title":"Lancet Oncol","first-page":"239","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019;20:239\u2013253."},{"key":"B157","series-title":"Lancet Respir Med","first-page":"260","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst MJ","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019;7:260\u2013270."},{"key":"B158","series-title":"J Clin Oncol","first-page":"1698","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem J","year":"2008","unstructured":"Jassem J, Ramlau R, Santoro A, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698\u20131704."},{"key":"B159","series-title":"Cancer","first-page":"2577","article-title":"A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"van Meerbeeck JP","year":"1999","unstructured":"van Meerbeeck JP, Baas P, Debruyne C, A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577\u20132582."},{"key":"B160","series-title":"Lancet Oncol","first-page":"1438","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto C","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021;22:1438\u20131447."},{"key":"B161","series-title":"Lung Cancer","first-page":"94","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing J","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K, The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009;63:94\u201397."},{"key":"B162","series-title":"Lung Cancer","first-page":"271","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer MG","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K, Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014;84:271\u2013274."},{"key":"B163","series-title":"Ann Oncol","first-page":"1734","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat S","year":"2020","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020;31:1734\u20131745."},{"key":"B164","series-title":"Expert Rev Respir Med","first-page":"533","article-title":"Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review","volume":"9","author":"Abdel-Rahman O","year":"2015","unstructured":"Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med 2015;9:533\u2013549."},{"key":"B165","series-title":"Lung Cancer","first-page":"360","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali PA","year":"2012","unstructured":"Zucali PA, Simonelli M, Michetti G, Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012;75:360\u2013367."},{"key":"B166","series-title":"J Thorac Oncol","first-page":"1304","article-title":"Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group","volume":"6","author":"Rice D","year":"2011","unstructured":"Rice D, Rusch V, Pass H, Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011;6:1304\u20131312."},{"key":"B167","series-title":"J Surg Oncol","first-page":"1178","article-title":"Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma","volume":"118","author":"van Gerwen M","year":"2018","unstructured":"van Gerwen M, Wolf A, Liu B, Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma. J Surg Oncol 2018;118:1178\u20131187."},{"key":"B168","series-title":"J Thorac Dis","first-page":"5423","article-title":"Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery","volume":"9","author":"Taioli E","year":"2017","unstructured":"Taioli E, van Gerwen M, Mihalopoulos M, Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery. J Thorac Dis 2017;9:5423\u20135433."},{"key":"B169","series-title":"J R Soc Med","first-page":"69","article-title":"A systematic review of lung-sparing extirpative surgery for pleural mesothelioma","volume":"104","author":"Teh E","year":"2011","unstructured":"Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med 2011;104:69\u201380."},{"key":"B170","series-title":"Lung Cancer","first-page":"240","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao C","year":"2014","unstructured":"Cao C, Tian D, Park J, A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014;83:240\u2013245."},{"key":"B171","series-title":"J Thorac Oncol","first-page":"390","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients","volume":"9","author":"Bovolato P","year":"2014","unstructured":"Bovolato P, Casadio C, Bille A, Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014;9:390\u2013396."},{"key":"B172","series-title":"Curr Treat Options Oncol","first-page":"201","article-title":"Surgical treatment of malignant pleural mesothelioma","volume":"12","author":"Kaufman AJ","year":"2011","unstructured":"Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol 2011;12:201\u2013216."},{"key":"B173","series-title":"Lancet Oncol","first-page":"713","article-title":"Surgery for mesothelioma? The debate continues","volume":"12","author":"Kindler HL.","year":"2011","unstructured":"Kindler HL. Surgery for mesothelioma? The debate continues. Lancet Oncol 2011;12:713\u2013714."},{"key":"B174","series-title":"Recent Results Cancer Res","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-642-10862-4_7","article-title":"Surgical therapy of mesothelioma","volume":"189","author":"Rice D.","year":"2011","unstructured":"Rice D. Surgical therapy of mesothelioma. Recent Results Cancer Res 2011;189:97\u2013125."},{"key":"B175","series-title":"Lung Cancer","first-page":"157","article-title":"Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary","volume":"48","author":"Maziak DE","year":"2005","unstructured":"Maziak DE, Gagliardi A, Haynes AE, Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157\u2013169."},{"key":"B176","series-title":"Eur J Cardiothorac Surg","first-page":"1031","article-title":"Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma","volume":"41","author":"Nakas A","year":"2012","unstructured":"Nakas A, von Meyenfeldt E, Lau K, Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg 2012;41:1031\u20131036."},{"key":"B177","series-title":"J Thorac Cardiovasc Surg","first-page":"620","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores RM","year":"2008","unstructured":"Flores RM, Pass HI, Seshan VE, Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620\u2013626, 626.e1\u20133."},{"key":"B178","series-title":"Ann Thorac Surg","first-page":"257","article-title":"Malignant pleural mesothelioma: surgical management in 285 patients","volume":"85","author":"Schipper PH","year":"2008","unstructured":"Schipper PH, Nichols FC, Thomse KM, Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257\u2013264; discussion 264."},{"key":"B179","series-title":"Ann Thorac Surg","first-page":"200","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication for malignant pleural mesothelioma","volume":"113","author":"Zhou N","year":"2022","unstructured":"Zhou N, Rice DC, Tsao AS, Extrapleural pneumonectomy versus pleurectomy\/decortication for malignant pleural mesothelioma. Ann Thorac Surg 2022;113:200\u2013208."},{"key":"B180","series-title":"Updates Surg","first-page":"1827","article-title":"Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy\/decortication (P\/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR)","volume":"74","author":"Magouliotis DE","year":"2022","unstructured":"Magouliotis DE, Zotos PA, Rad AA, Meta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy\/decortication (P\/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR). Updates Surg 2022;74:1827\u20131837."},{"key":"B181","series-title":"J Thorac Cardiovasc Surg","first-page":"54","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"Sugarbaker DJ","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT, Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54\u201363; discussion 63\u201365."},{"key":"B182","series-title":"J Thorac Cardiovasc Surg","first-page":"788","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch VW","year":"2001","unstructured":"Rusch VW, Rosenzweig K, Venkatraman E, A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788\u2013795."},{"key":"B183","series-title":"Ann Surg","first-page":"1212","article-title":"Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients","volume":"275","author":"Lapidot M","year":"2022","unstructured":"Lapidot M, Gill RR, Mazzola E, Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients. Ann Surg 2022;275:1212\u20131220."},{"key":"B184","series-title":"Ann Thorac Surg","first-page":"194","article-title":"Is there a role for cancer-directed surgery in early-stage sarcomatoid or biphasic mesothelioma?","volume":"107","author":"Kim S","year":"2019","unstructured":"Kim S, Bull DA, Garland L, Is there a role for cancer-directed surgery in early-stage sarcomatoid or biphasic mesothelioma? Ann Thorac Surg 2019;107:194\u2013201."},{"key":"B185","series-title":"Lancet Oncol","first-page":"763","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure T","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763\u2013772."},{"key":"B186","series-title":"Lancet Respir Med","first-page":"457","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim E","year":"2024","unstructured":"Lim E, Waller D, Lau K, Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med 2024;12:457\u2013466."},{"key":"B187","series-title":"Lancet Oncol","first-page":"1093","article-title":"The MARS feasibility trial: conclusions not supported by data","volume":"12","author":"Weder W","year":"2011","unstructured":"Weder W, Stahel RA, Baas P, The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093\u20131094; author reply 1094\u20131095."},{"key":"B188","series-title":"BMJ Open","first-page":"e038892","article-title":"Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma","volume":"10","author":"Lim E","year":"2020","unstructured":"Lim E, Darlison L, Edwards J, Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020;10:e038892."},{"key":"B189","series-title":"Ann Thorac Surg","first-page":"1859","article-title":"Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study","volume":"97","author":"Spaggiari L","year":"2014","unstructured":"Spaggiari L, Marulli G, Bovolato P, Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg 2014;97:1859\u20131865."},{"key":"B190","series-title":"J Thorac Oncol","first-page":"1649","article-title":"Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population","volume":"5","author":"Flores RM","year":"2010","unstructured":"Flores RM, Riedel E, Donington JS, Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol 2010;5:1649\u20131654."},{"key":"B191","series-title":"Radiother Oncol","first-page":"1","article-title":"The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review","volume":"125","author":"Ashton M","year":"2017","unstructured":"Ashton M, O\u2019Rourke N, Currie S, The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review. Radiother Oncol 2017;125:1\u201312."},{"key":"B192","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1368","article-title":"Radical hemithoracic radiotherapy versus palliative radiotherapy in non-metastatic malignant pleural mesothelioma: results from a phase 3 randomized clinical trial","volume":"109","author":"Trovo M","year":"2021","unstructured":"Trovo M, Relevant A, Polesel J, Radical hemithoracic radiotherapy versus palliative radiotherapy in non-metastatic malignant pleural mesothelioma: results from a phase 3 randomized clinical trial. Int J Radiat Oncol Biol Phys 2021;109:1368\u20131376."},{"key":"B193","series-title":"J Clin Oncol","first-page":"2761","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (imprint) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner A","year":"2016","unstructured":"Rimner A, Zauderer MG, Gomez DR, Phase II study of hemithoracic intensity-modulated pleural radiation therapy (imprint) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2016;34:2761\u20132768."},{"key":"B194","series-title":"Int J Radiat Oncol Biol Phys","first-page":"606","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel E","year":"2015","unstructured":"Minatel E, Trovo M, Bearz A, Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys 2015;93:606\u2013613."},{"key":"B195","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1278","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig KE","year":"2012","unstructured":"Rosenzweig KE, Zauderer MG, Laser B, Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2012;83:1278\u20131283."},{"key":"B196","series-title":"J Thorac Oncol","first-page":"993","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"Shaikh F","year":"2017","unstructured":"Shaikh F, Zauderer MG, von Reibnitz D, Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2017;12:993\u20131000."},{"key":"B197","series-title":"Oncologist","first-page":"359","article-title":"What is the role of radiotherapy in malignant pleural mesothelioma?","volume":"16","author":"Price A.","year":"2011","unstructured":"Price A. What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist 2011;16:359\u2013365."},{"key":"B198","series-title":"Semin Thorac Cardiovasc Surg","first-page":"159","article-title":"Radiation therapy options for malignant pleural mesothelioma","volume":"21","author":"Baldini EH.","year":"2009","unstructured":"Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:159\u2013163."},{"key":"B199","series-title":"J Thorac Oncol","first-page":"1172","article-title":"The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"14","author":"Gomez DR","year":"2019","unstructured":"Gomez DR, Rimner A, Simone CB, The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 2019;14:1172\u20131183."},{"key":"B200","series-title":"Radiat Oncol","first-page":"267","article-title":"Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy","volume":"10","author":"Thieke C","year":"2015","unstructured":"Thieke C, Nicolay NH, Sterzing F, Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol 2015;10:267."},{"key":"B201","series-title":"Int J Radiat Oncol Biol Phys","first-page":"149","article-title":"Hemithoracic intensity modulated radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis","volume":"91","author":"Chance WW","year":"2015","unstructured":"Chance WW, Rice DC, Allen PK, Hemithoracic intensity modulated radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys 2015;91:149\u2013156."},{"key":"B202","series-title":"J Thorac Oncol","first-page":"238","article-title":"Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"8","author":"Gomez DR","year":"2013","unstructured":"Gomez DR, Hong DS, Allen PK, Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol 2013;8:238\u2013245."},{"key":"B203","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1319","article-title":"Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"56","author":"Yajnik S","year":"2003","unstructured":"Yajnik S, Rosenzweig KE, Mychalczak B, Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003;56:1319\u20131326."},{"key":"B204","series-title":"World J Clin Oncol","first-page":"581","article-title":"GOECP\/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma","volume":"12","author":"Luna J","year":"2021","unstructured":"Luna J, Bobo A, Cabrera-Rodriguez JJ, GOECP\/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma. World J Clin Oncol 2021;12:581\u2013608."},{"key":"B205","series-title":"Lung Cancer","first-page":"75","article-title":"Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin\/Pemetrexed and radiotherapy","volume":"71","author":"Bolukbas S","year":"2011","unstructured":"Bolukbas S, Manegold C, Eberlein M, Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin\/Pemetrexed and radiotherapy. Lung Cancer 2011;71:75\u201381."},{"key":"B206","series-title":"J Thorac Oncol","first-page":"1010","article-title":"Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia","volume":"4","author":"Hasani A","year":"2009","unstructured":"Hasani A, Alvarez JM, Wyatt JM, Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010\u20131016."},{"key":"B207","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1045","article-title":"Hemithoracic radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma","volume":"63","author":"Gupta V","year":"2005","unstructured":"Gupta V, Mychalczak B, Krug L, Hemithoracic radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045\u20131052."},{"key":"B208","series-title":"J Thorac Oncol","first-page":"746","article-title":"Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy","volume":"4","author":"Gupta V","year":"2009","unstructured":"Gupta V, Krug LM, Laser B, Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009;4:746\u2013750."},{"key":"B209","series-title":"Ann Thorac Surg","first-page":"334","article-title":"Patterns of failure after trimodality therapy for malignant pleural mesothelioma","volume":"63","author":"Baldini EH","year":"1997","unstructured":"Baldini EH, Recht A, Strauss GM, Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334\u2013338."},{"key":"B210","series-title":"J Thorac Oncol","first-page":"944","article-title":"Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial","volume":"10","author":"MacLeod N","year":"2015","unstructured":"MacLeod N, Chalmers A, O\u2019Rourke N, Is radiotherapy useful for treating pain in mesothelioma?: A phase II trial. J Thorac Oncol 2015;10:944\u2013950."},{"key":"B211","series-title":"Clin Transl Radiat Oncol","first-page":"45","article-title":"SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma","volume":"8","author":"Ashton M","year":"2018","unstructured":"Ashton M, O\u2019Rourke N, Macleod N, SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Clin Transl Radiat Oncol 2018;8:45\u201349."},{"key":"B212","series-title":"Pract Radiat Oncol","first-page":"119","article-title":"Consensus statement on proton therapy in mesothelioma","volume":"11","author":"Zeng J","year":"2021","unstructured":"Zeng J, Badiyan SN, Garces YI, Consensus statement on proton therapy in mesothelioma. Pract Radiat Oncol 2021;11:119\u2013133."},{"key":"B213","series-title":"Front Oncol","first-page":"961","article-title":"Stereotactic body radiation therapy (SBRT) as salvage therapy for oligorecurrent pleural mesothelioma after multi-modality therapy","volume":"9","author":"Schroder C","year":"2019","unstructured":"Schroder C, Opitz I, Guckenberger M, Stereotactic body radiation therapy (SBRT) as salvage therapy for oligorecurrent pleural mesothelioma after multi-modality therapy. Front Oncol 2019;9:961."},{"key":"B214","series-title":"Int J Radiat Oncol Biol Phys","first-page":"350","article-title":"Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"69","author":"Rice DC","year":"2007","unstructured":"Rice DC, Smythe WR, Liao Z, Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:350\u2013357."},{"key":"B215","series-title":"Ann Thorac Surg","first-page":"1685","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice DC","year":"2007","unstructured":"Rice DC, Stevens CW, Correa AM, Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685\u20131692; discussion 1692\u20131693."},{"key":"B216","series-title":"Int J Radiat Oncol Biol Phys","first-page":"640","article-title":"Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma","volume":"65","author":"Allen AM","year":"2006","unstructured":"Allen AM, Czerminska M, Janne PA, Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640\u2013645."},{"key":"B217","series-title":"Radiother Oncol","first-page":"96","article-title":"Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"92","author":"Kristensen CA","year":"2009","unstructured":"Kristensen CA, Nottrup TJ, Berthelsen AK, Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009;92:96\u201399."},{"key":"B218","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1143","article-title":"Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience","volume":"71","author":"Miles EF","year":"2008","unstructured":"Miles EF, Larrier NA, Kelsey CR, Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 2008;71:1143\u20131150."},{"key":"B219","series-title":"Int J Radiat Oncol Biol Phys","first-page":"362","article-title":"Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy","volume":"83","author":"Patel PR","year":"2012","unstructured":"Patel PR, Yoo S, Broadwater G, Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:362\u2013368."},{"key":"B220","series-title":"Ann Oncol","first-page":"v126","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Stahel RA","year":"2010","unstructured":"Stahel RA, Weder W, Lievens Y, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v126\u2013128."},{"key":"B221","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1593","article-title":"Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy","volume":"69","author":"Krayenbuehl J","year":"2007","unstructured":"Krayenbuehl J, Oertel S, Davis JB, Ciernik IF. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys 2007;69:1593\u20131599."},{"key":"B222","series-title":"Chest","first-page":"754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy","volume":"108","author":"Boutin C","year":"1995","unstructured":"Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754\u2013758."},{"key":"B223","series-title":"Int J Radiat Oncol Biol Phys","first-page":"511","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura\u2013a single-institution experience with 189 patients","volume":"43","author":"de Graaf-Strukowska L","year":"1999","unstructured":"de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura\u2013a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511\u2013516."},{"key":"B224","series-title":"Acta Oncol","first-page":"1094","article-title":"Prevention of malignant seeding at drain sites after invasive procedures (surgery and\/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma","volume":"47","author":"Di Salvo M","year":"2008","unstructured":"Di Salvo M, Gambaro G, Pagella S, Prevention of malignant seeding at drain sites after invasive procedures (surgery and\/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma. Acta Oncol 2008;47:1094\u20131098."},{"key":"B225","series-title":"Curr Opin Pulm Med","first-page":"326","article-title":"Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues","volume":"14","author":"Davies HE","year":"2008","unstructured":"Davies HE, Musk AW, Lee YC. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Opin Pulm Med 2008;14:326\u2013330."},{"key":"B226","series-title":"Radiother Oncol","first-page":"18","article-title":"A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O\u2019Rourke N","year":"2007","unstructured":"O\u2019Rourke N, Garcia JC, Paul J, A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84:18\u201322."},{"key":"B227","series-title":"Br J Cancer","first-page":"9","article-title":"A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder S","year":"2004","unstructured":"Bydder S, Phillips M, Joseph DJ, A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004;91:9\u201310."},{"key":"B228","series-title":"Lancet Oncol","first-page":"1094","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive AO","year":"2016","unstructured":"Clive AO, Taylor H, Dobson L, Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol 2016;17:1094\u20131104."},{"key":"B229","article-title":"AJCC Cancer Staging System: Diffuse Pleural Mesothelioma (Version 9 of the AJCC Cancer Staging System)","author":"Rusch V","year":"2024","unstructured":"Rusch V, Giroux D, Bille A, AJCC Cancer Staging System: Diffuse Pleural Mesothelioma (Version 9 of the AJCC Cancer Staging System). Chicago, IL: American College of Surgeons; 2024."},{"key":"B230","series-title":"Am J Clin Oncol","first-page":"4","article-title":"The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy","volume":"13","author":"Ball DL","year":"1990","unstructured":"Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4\u20139."},{"key":"B231","series-title":"J Vasc Interv Radiol","first-page":"213","article-title":"Percutaneous cryoablation for the treatment of recurrent malignant pleural mesothelioma: safety, early-term efficacy, and predictors of local recurrence","volume":"28","author":"Abtin F","year":"2017","unstructured":"Abtin F, Quirk MT, Suh RD, Percutaneous cryoablation for the treatment of recurrent malignant pleural mesothelioma: safety, early-term efficacy, and predictors of local recurrence. J Vasc Interv Radiol 2017;28:213\u2013221."},{"key":"B232","series-title":"Respirology","first-page":"649","article-title":"Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series","volume":"10","author":"Aelony Y","year":"2005","unstructured":"Aelony Y, Yao JF. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series. Respirology 2005;10:649\u2013655."},{"key":"B233","series-title":"Ann Thorac Surg","first-page":"1809","article-title":"Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients","volume":"71","author":"Schulze M","year":"2001","unstructured":"Schulze M, Boehle AS, Kurdow R, Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg 2001;71:1809\u20131812."},{"key":"B234","series-title":"Cancer","first-page":"801","article-title":"Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting","volume":"75","author":"Petrou M","year":"1995","unstructured":"Petrou M, Kaplan D, Goldstraw P. Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting. Cancer 1995;75:801\u2013805."},{"key":"B235","series-title":"J Clin Oncol","first-page":"3007","article-title":"Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma","volume":"27","author":"Krug LM","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW, Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007\u20133013."},{"key":"B236","series-title":"Ann Oncol","first-page":"1196","article-title":"Multicenter trial of neo- adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma","volume":"18","author":"Weder W","year":"2007","unstructured":"Weder W, Stahel RA, Bernhard J, Multicenter trial of neo- adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196\u20131202."},{"key":"B237","series-title":"Eur Respir J","first-page":"2302114","article-title":"A randomised phase II study of extended pleurectomy\/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205","volume":"63","author":"Raskin J","year":"2024","unstructured":"Raskin J, Surmont V, Maat A, A randomised phase II study of extended pleurectomy\/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205. Eur Respir J 2024;63:2302114."},{"key":"B238","series-title":"Am J Clin Oncol","first-page":"30","article-title":"Trimodality treatment of malignant pleural mesothelioma: an institutional review","volume":"41","author":"Kapeles M","year":"2018","unstructured":"Kapeles M, Gensheimer MF, Mart DA, Trimodality treatment of malignant pleural mesothelioma: an institutional review. Am J Clin Oncol 2018;41:30\u201335."},{"key":"B239","series-title":"J Clin Oncol","first-page":"3354","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson DB","year":"2017","unstructured":"Nelson DB, Rice DC, Niu J, Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis. J Clin Oncol 2017;35:3354\u20133362."},{"key":"B240","series-title":"J Clin Oncol","first-page":"1413","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"27","author":"de Perrot M","year":"2009","unstructured":"de Perrot M, Feld R, Cho BC, Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413\u20131418."},{"key":"B241","article-title":"About ClinicalTrials.gov","unstructured":"ClinicalTrials.gov. About ClinicalTrials.gov. Accessed May 1, 2026. Available at: https:\/\/clinicaltrials.gov\/about-site\/about-ctg"},{"key":"B242","series-title":"J Thorac Oncol","first-page":"1631","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch VW","year":"2012","unstructured":"Rusch VW, Giroux D, Kennedy C, Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7:1631\u20131639."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/8\/article-e260038.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/8\/article-e260038.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/8\/article-e260038.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:56:20Z","timestamp":1786971380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/8\/article-e260038.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":242,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0038","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}